A French randomized trial found healthy, low-risk people over 75 who stopped their preventive statins were no worse off on death or heart events over three years — with big caveats.
In lab-infected human immune cells, dexamethasone dialed down damaging inflammation from a stubborn lung infection while still letting the cells fight the bacteria.
The nationwide recall covers one lot of Tyenne (tocilizumab-aazg) injection after glass particles were found in the vials, a risk of irritation or vein inflammation.
K2 Therapeutics, a Flagship-style ‘hub-and-spoke’ biotech that in-licenses drug candidates worldwide, named the former Legend Biotech chief as its new leader.
BeOne gains Asian rights to Revolution’s RAS(ON) inhibitors and will test them with its own oncology drugs against some of cancer’s hardest targets.
Structure Therapeutics’ once-daily oral drug aleniglipron cut body weight by 12.1% over 36 weeks — a convenient, needle-free take on the blockbuster GLP-1 class.
Sobi gains commercial rights to lacutamab, a first-in-class antibody for cutaneous T-cell lymphoma now in a Phase 3 confirmatory trial and heading for accelerated approval.
The multi-modality site — making small molecules, biologics and antibody-drug conjugates — is part of BMS’s $40 billion U.S. push amid tariffs and reshoring.
The deal adds ABS-1230, an oral drug for KCNT1-related epilepsy that has no approved treatment — Jazz’s second epilepsy acquisition in a year.
Vanderbilt and TGen researchers used spatial transcriptomics on biopsy tissue to expose molecular variation within the same rejection grades — and flag who won’t respond to standard therapy.
A 12-week randomized study in adults with overweight found three daily servings of full-fat dairy didn’t harm cholesterol or body composition — but it was short and industry-funded.
The Nav1.8-inhibitor developer priced at the top of its range to fund a Phase 3-ready pain drug meant to rival Vertex’s Journavx, as biotech IPOs keep rolling.